Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Erratum: Flipping the cyclooxygenase (Ptgs) genes reveals isoform-specific compensatory functions.

Li X, Mazaleuskaya LL, Yuan C, Ballantyne LL, Meng H, Smith WL, FitzGerald GA, Funk CD.

J Lipid Res. 2018 Oct;59(10):2035. doi: 10.1194/jlr.M079996ERR. No abstract available.

2.

Isoform-Specific Compensation of Cyclooxygenase (Ptgs) Genes during Implantation and Late-Stage Pregnancy.

Li X, Ballantyne LL, Crawford MC, FitzGerald GA, Funk CD.

Sci Rep. 2018 Aug 14;8(1):12097. doi: 10.1038/s41598-018-30636-x.

3.

Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration.

Liu G, Gong Y, Zhang R, Piao L, Li X, Liu Q, Yan S, Shen Y, Guo S, Zhu M, Yin H, Funk CD, Zhang J, Yu Y.

FASEB J. 2018 Oct;32(10):5413-5425. doi: 10.1096/fj.201800173R. Epub 2018 May 3.

PMID:
29723062
4.

Differential compensation of two cyclooxygenases in renal homeostasis is independent of prostaglandin-synthetic capacity under basal conditions.

Li X, Mazaleuskaya LL, Ballantyne LL, Meng H, FitzGerald GA, Funk CD.

FASEB J. 2018 Oct;32(10):5326-5337. doi: 10.1096/fj.201800252R. Epub 2018 Apr 20.

PMID:
29676940
5.

Transplantation of Gene-Edited Hepatocyte-like Cells Modestly Improves Survival of Arginase-1-Deficient Mice.

Sin YY, Ballantyne LL, Richmond CR, Funk CD.

Mol Ther Nucleic Acids. 2018 Mar 2;10:122-130. doi: 10.1016/j.omtn.2017.11.012. Epub 2017 Dec 1.

6.

Flipping the cyclooxygenase (Ptgs) genes reveals isoform-specific compensatory functions.

Li X, Mazaleuskaya LL, Yuan C, Ballantyne LL, Meng H, Smith WL, FitzGerald GA, Funk CD.

J Lipid Res. 2018 Jan;59(1):89-101. doi: 10.1194/jlr.M079996. Epub 2017 Nov 27. Erratum in: J Lipid Res. 2018 Oct;59(10):2035.

7.

Genomic and lipidomic analyses differentiate the compensatory roles of two COX isoforms during systemic inflammation in mice.

Li X, Mazaleuskaya LL, Ballantyne LL, Meng H, FitzGerald GA, Funk CD.

J Lipid Res. 2018 Jan;59(1):102-112. doi: 10.1194/jlr.M080028. Epub 2017 Nov 27.

8.

Early treatment with Resolvin E1 facilitates myocardial recovery from ischaemia in mice.

Liu G, Liu Q, Shen Y, Kong D, Gong Y, Tao B, Chen G, Guo S, Li J, Zuo S, Yu Y, Yin H, Zhang L, Zhou B, Funk CD, Zhang J, Yu Y.

Br J Pharmacol. 2018 Apr;175(8):1205-1216. doi: 10.1111/bph.14041. Epub 2017 Oct 22.

9.

Proof-of-Concept Gene Editing for the Murine Model of Inducible Arginase-1 Deficiency.

Sin YY, Price PR, Ballantyne LL, Funk CD.

Sci Rep. 2017 May 31;7(1):2585. doi: 10.1038/s41598-017-02927-2.

10.

Effects of p53-knockout in vascular smooth muscle cells on atherosclerosis in mice.

Cao RY, Eves R, Jia L, Funk CD, Jia Z, Mak AS.

PLoS One. 2017 Mar 31;12(3):e0175061. doi: 10.1371/journal.pone.0175061. eCollection 2017.

11.

Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency.

Ballantyne LL, Sin YY, Al-Dirbashi OY, Li X, Hurlbut DJ, Funk CD.

Mol Genet Metab Rep. 2016 Oct 12;9:54-60. eCollection 2016 Dec.

12.

The Moral Frameworks and Foundations of Contesting Orientations.

Shields DL, Funk CD, Bredemeier BL.

J Sport Exerc Psychol. 2016 Apr;38(2):117-27. doi: 10.1123/jsep.2015-0139. Epub 2016 Mar 15.

PMID:
27390163
13.

Thromboxane Governs the Differentiation of Adipose-Derived Stromal Cells Toward Endothelial Cells In Vitro and In Vivo.

Shen Y, Zuo S, Wang Y, Shi H, Yan S, Chen D, Xiao B, Zhang J, Gong Y, Shi M, Tang J, Kong D, Lu L, Yu Y, Zhou B, Duan SZ, Schneider C, Funk CD, Yu Y.

Circ Res. 2016 Apr 15;118(8):1194-207. doi: 10.1161/CIRCRESAHA.115.307853. Epub 2016 Mar 8.

PMID:
26957525
14.

Predictors of Moral Disengagement in Sport.

Shields DL, Funk CD, Bredemeier BL.

J Sport Exerc Psychol. 2015 Dec;37(6):646-58. doi: 10.1123/jsep.2015-0110.

PMID:
26866772
15.

Arginase-1 deficiency.

Sin YY, Baron G, Schulze A, Funk CD.

J Mol Med (Berl). 2015 Dec;93(12):1287-96. doi: 10.1007/s00109-015-1354-3. Epub 2015 Oct 14. Review.

PMID:
26467175
16.

Strategies to rescue the consequences of inducible arginase-1 deficiency in mice.

Ballantyne LL, Sin YY, St Amand T, Si J, Goossens S, Haenebalcke L, Haigh JJ, Kyriakopoulou L, Schulze A, Funk CD.

PLoS One. 2015 May 4;10(5):e0125967. doi: 10.1371/journal.pone.0125967. eCollection 2015.

17.

Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction with free fatty acid receptor 4 in mice.

Li X, Ballantyne LL, Che X, Mewburn JD, Kang JX, Barkley RM, Murphy RC, Yu Y, Funk CD.

J Am Heart Assoc. 2015 Apr 6;4(4). pii: e001856. doi: 10.1161/JAHA.115.001856.

18.

EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Lu A, Zuo C, He Y, Chen G, Piao L, Zhang J, Xiao B, Shen Y, Tang J, Kong D, Alberti S, Chen D, Zuo S, Zhang Q, Yan S, Fei X, Yuan F, Zhou B, Duan S, Yu Y, Lazarus M, Su Y, Breyer RM, Funk CD, Yu Y.

J Clin Invest. 2015 Mar 2;125(3):1228-42. doi: 10.1172/JCI77656. Epub 2015 Feb 9.

19.

Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling.

Gong Y, Lin M, Piao L, Li X, Yang F, Zhang J, Xiao B, Zhang Q, Song WL, Yin H, Zhu L, Funk CD, Yu Y.

Br J Pharmacol. 2015 Dec;172(23):5647-60. doi: 10.1111/bph.12986. Epub 2015 Jan 12.

20.

Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice.

Shi M, Shi G, Tang J, Kong D, Bao Y, Xiao B, Zuo C, Wang T, Wang Q, Shen Y, Wang H, Funk CD, Zhou J, Yu Y.

J Allergy Clin Immunol. 2014 Nov;134(5):1163-74.e16. doi: 10.1016/j.jaci.2014.04.035. Epub 2014 Jun 17.

PMID:
24948368
21.

Whole blood transcriptomics and urinary metabolomics to define adaptive biochemical pathways of high-intensity exercise in 50-60 year old masters athletes.

Mukherjee K, Edgett BA, Burrows HW, Castro C, Griffin JL, Schwertani AG, Gurd BJ, Funk CD.

PLoS One. 2014 Mar 18;9(3):e92031. doi: 10.1371/journal.pone.0092031. eCollection 2014.

22.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

23.

A mutation interfering with 5-lipoxygenase domain interaction leads to increased enzyme activity.

Rakonjac Ryge M, Tanabe M, Provost P, Persson B, Chen X, Funk CD, Rinaldo-Matthis A, Hofmann B, Steinhilber D, Watanabe T, Samuelsson B, Rådmark O.

Arch Biochem Biophys. 2014 Mar 1;545:179-85. doi: 10.1016/j.abb.2014.01.017. Epub 2014 Jan 28.

PMID:
24480307
24.

Multiple-site activation of the cysteinyl leukotriene receptor 2 is required for exacerbation of ischemia/reperfusion injury.

Ni NC, Ballantyne LL, Mewburn JD, Funk CD.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):321-30. doi: 10.1161/ATVBAHA.113.302536. Epub 2013 Nov 27.

PMID:
24285579
25.

Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism.

Sin YY, Ballantyne LL, Mukherjee K, St Amand T, Kyriakopoulou L, Schulze A, Funk CD.

PLoS One. 2013 Nov 4;8(11):e80001. doi: 10.1371/journal.pone.0080001. eCollection 2013.

26.

Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4).

Li X, Yu Y, Funk CD.

FASEB J. 2013 Dec;27(12):4987-97. doi: 10.1096/fj.13-235333. Epub 2013 Sep 4.

PMID:
24005906
27.

Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor.

Zhang J, Zou F, Tang J, Zhang Q, Gong Y, Wang Q, Shen Y, Xiong L, Breyer RM, Lazarus M, Funk CD, Yu Y.

Circ Res. 2013 Jul 5;113(2):104-14. doi: 10.1161/CIRCRESAHA.113.301033. Epub 2013 Apr 17.

28.

Ex vivo Akt/HO-1 gene therapy to human endothelial progenitor cells enhances myocardial infarction recovery.

Brunt KR, Wu J, Chen Z, Poeckel D, Dercho RA, Melo LG, Funk CD, Ward CA, Li RK.

Cell Transplant. 2012;21(7):1443-61.

PMID:
22776314
29.

Development of myeloproliferative disease in 12/15-lipoxygenase deficiency.

Taylor PR, Heydeck D, Jones GW, Krönke G, Funk CD, Knapper S, Adams D, Kühn H, O'Donnell VB.

Blood. 2012 Jun 21;119(25):6173-4; author reply 6174-5. doi: 10.1182/blood-2012-02-410928. No abstract available.

30.

Prostaglandin receptor EP4 in abdominal aortic aneurysms.

Cao RY, St Amand T, Li X, Yoon SH, Wang CP, Song H, Maruyama T, Brown PM, Zelt DT, Funk CD.

Am J Pathol. 2012 Jul;181(1):313-21. doi: 10.1016/j.ajpath.2012.03.016. Epub 2012 May 15.

PMID:
22595380
31.

Targeted exchange of an expression cassette encoding cyclooxygenase-2 at the Ptgs1 locus.

Li X, Guo M, McCracken CM, Funk CD.

Prostaglandins Other Lipid Mediat. 2012 Oct;99(1-2):38-44. doi: 10.1016/j.prostaglandins.2012.04.003. Epub 2012 May 1.

PMID:
22579447
32.

Vascular COX-2 modulates blood pressure and thrombosis in mice.

Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Puré E, Funk CD, FitzGerald GA.

Sci Transl Med. 2012 May 2;4(132):132ra54. doi: 10.1126/scitranslmed.3003787.

33.

Hemodynamics of the mouse abdominal aortic aneurysm.

Ford MD, Black AT, Cao RY, Funk CD, Piomelli U.

J Biomech Eng. 2011 Dec;133(12):121008. doi: 10.1115/1.4005477.

PMID:
22206425
34.

The cysteinyl leukotriene 2 receptor mediates retinal edema and pathological neovascularization in a murine model of oxygen-induced retinopathy.

Barajas-Espinosa A, Ni NC, Yan D, Zarini S, Murphy RC, Funk CD.

FASEB J. 2012 Mar;26(3):1100-9. doi: 10.1096/fj.11-195792. Epub 2011 Nov 30.

PMID:
22131271
35.

Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease.

Haeggström JZ, Funk CD.

Chem Rev. 2011 Oct 12;111(10):5866-98. doi: 10.1021/cr200246d. Epub 2011 Sep 22. Review. No abstract available.

PMID:
21936577
36.

A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice.

Ni NC, Yan D, Ballantyne LL, Barajas-Espinosa A, St Amand T, Pratt DA, Funk CD.

J Pharmacol Exp Ther. 2011 Dec;339(3):768-78. doi: 10.1124/jpet.111.186031. Epub 2011 Sep 8.

PMID:
21903747
37.

Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline.

Seta F, Rahmani M, Turner PV, Funk CD.

PLoS One. 2011;6(8):e23439. doi: 10.1371/journal.pone.0023439. Epub 2011 Aug 5.

38.

Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract.

Barajas-Espinosa A, Ochoa-Cortes F, Moos MP, Ramirez FD, Vanner SJ, Funk CD.

Am J Pathol. 2011 Jun;178(6):2682-9. doi: 10.1016/j.ajpath.2011.02.041.

39.

Leukotriene inflammatory mediators meet their match.

Funk CD.

Sci Transl Med. 2011 Jan 19;3(66):66ps3. doi: 10.1126/scitranslmed.3002040.

PMID:
21248314
40.

Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.

Yan D, Stocco R, Sawyer N, Nesheim ME, Abramovitz M, Funk CD.

Mol Pharmacol. 2011 Feb;79(2):270-8. doi: 10.1124/mol.110.069054. Epub 2010 Nov 15.

PMID:
21078884
41.

Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease.

Martínez-Clemente M, Ferré N, Titos E, Horrillo R, González-Périz A, Morán-Salvador E, López-Vicario C, Miquel R, Arroyo V, Funk CD, Clària J.

Hepatology. 2010 Dec;52(6):1980-91. doi: 10.1002/hep.23928. Epub 2010 Oct 21.

PMID:
20967760
42.

5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice.

Martínez-Clemente M, Ferré N, González-Périz A, López-Parra M, Horrillo R, Titos E, Morán-Salvador E, Miquel R, Arroyo V, Funk CD, Clària J.

Hepatology. 2010 Mar;51(3):817-27. doi: 10.1002/hep.23463.

PMID:
20112424
43.

The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.

Poeckel D, Funk CD.

Cardiovasc Res. 2010 May 1;86(2):243-53. doi: 10.1093/cvr/cvq016. Epub 2010 Jan 21. Review.

PMID:
20093252
44.

The Murine Angiotensin II-Induced Abdominal Aortic Aneurysm Model: Rupture Risk and Inflammatory Progression Patterns.

Cao RY, Amand T, Ford MD, Piomelli U, Funk CD.

Front Pharmacol. 2010 Jul 14;1:9. doi: 10.3389/fphar.2010.00009. eCollection 2010.

45.

Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice.

Yu Y, Stubbe J, Ibrahim S, Song WL, Smyth EM, Funk CD, FitzGerald GA.

Circ Res. 2010 Feb 5;106(2):337-45. doi: 10.1161/CIRCRESAHA.109.204529. Epub 2009 Nov 25. Erratum in: Circ Res. 2010 Nov 12;107(10):e19. Symth, Emer M [corrected to Smyth, Emer M].

46.

A cell-based assay for screening lipoxygenase inhibitors.

Nair DG, Funk CD.

Prostaglandins Other Lipid Mediat. 2009 Dec;90(3-4):98-104. doi: 10.1016/j.prostaglandins.2009.09.006. Epub 2009 Oct 3.

PMID:
19804839
47.

Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice.

Poeckel D, Zemski Berry KA, Murphy RC, Funk CD.

J Biol Chem. 2009 Jul 31;284(31):21077-89. doi: 10.1074/jbc.M109.000901. Epub 2009 Jun 9.

48.

Renal and cardiovascular characterization of COX-2 knockdown mice.

Seta F, Chung AD, Turner PV, Mewburn JD, Yu Y, Funk CD.

Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1751-60. doi: 10.1152/ajpregu.90985.2008. Epub 2009 Apr 8.

49.

Endothelial cysteinyl leukotriene 2 receptor expression and myocardial ischemia/reperfusion injury.

Moos MP, Funk CD.

Trends Cardiovasc Med. 2008 Oct;18(7):268-73. doi: 10.1016/j.tcm.2008.11.009. Review.

PMID:
19232956
50.

Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice.

Cao RY, St Amand T, Gräbner R, Habenicht AJ, Funk CD.

Atherosclerosis. 2009 Apr;203(2):395-400. doi: 10.1016/j.atherosclerosis.2008.07.045. Epub 2008 Aug 15.

PMID:
18804760

Supplemental Content

Support Center